2024
Disparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum.
Steiger K, Herrin J, Swarna K, Davis E, McCoy R. Disparities in Acute and Chronic Complications of Diabetes Along the U.S. Rural-Urban Continuum. Diabetes Care 2024, 47: 818-825. PMID: 38387066, PMCID: PMC11043221, DOI: 10.2337/dc23-1552.Peer-Reviewed Original ResearchResidents of remote areasRural-urban continuumHazard ratioLower-extremity complicationsHazard of myocardial infarctionMedicare Advantage beneficiariesRemote areasHazard of strokeOptumLabs Data WarehouseComplications of diabetesLower hazardMyocardial infarctionRetrospective cohort studyHeart failureDiabetic complicationsCohort studyResidents of small townsEnd-stage kidney diseaseSmall townsChronic complications of diabetesChronic diabetic complicationsResidentsDiabetesDisparitiesChronic complicationsNational Estimates of Short- and Longer-Term Hospital Readmissions After Major Surgery Among Community-Living Older Adults
Wang Y, Leo-Summers L, Vander Wyk B, Davis-Plourde K, Gill T, Becher R. National Estimates of Short- and Longer-Term Hospital Readmissions After Major Surgery Among Community-Living Older Adults. JAMA Network Open 2024, 7: e240028. PMID: 38416499, PMCID: PMC10902728, DOI: 10.1001/jamanetworkopen.2024.0028.Peer-Reviewed Original ResearchConceptsCenters for Medicare & Medicaid ServicesFee-for-serviceMedicare Advantage beneficiariesHospital readmissionUS residentsNational Health and Aging Trends Study dataCommunity-living older adultsProspective longitudinal cohort studyCommunity-living participantsRate of hospital readmissionLikelihood of hospital readmissionPopulation-based estimatesNationally representative estimatesSex-adjusted modelsCommunity-livingData linkageGeriatric conditionsMedicaid ServicesOlder personsOlder adultsMain OutcomesNational estimatesRepresentative estimatesData analysisCohort study
2023
1358-P: Disparities in Acute and Chronic Complications of Diabetes in Rural U.S.
STEIGER K, HERRIN J, SWARNA K, MCCOY R. 1358-P: Disparities in Acute and Chronic Complications of Diabetes in Rural U.S. Diabetes 2023, 72 DOI: 10.2337/db23-1358-p.Peer-Reviewed Original ResearchChronic diabetes complicationsDiabetes complicationsKidney diseaseMyocardial infarctionGreater incidenceEnd-stage kidney diseaseIncidence of strokeRate of complicationsLower extremity ulcersDiabetes-related complicationsHealth care utilizationOptumLabs Data WarehouseMedicare Advantage beneficiariesChronic complicationsCharcot jointExtremity ulcersHeart failureSevere hypoglycemiaCare utilizationSevere hyperglycemiaAtrial fibrillationLower incidenceComplicationsHigh incidenceDiabetes65-OR: Differences in the Use of Diabetes Medications with Cardiorenal Benefits between Rural and Urban America
STEIGER K, SWARNA K, HERRIN J, MCCOY R. 65-OR: Differences in the Use of Diabetes Medications with Cardiorenal Benefits between Rural and Urban America. Diabetes 2023, 72 DOI: 10.2337/db23-65-or.Peer-Reviewed Original ResearchGLP-1 RAsType 2 diabetesDiabetes medicationsCardiorenal benefitsMedication useKidney diseaseNew glucose-lowering medicationsDiabetes medication useMultiple biopsychosocial factorsGlucose-lowering medicationsChronic kidney diseaseDiabetes-related complicationsLow-income patientsMedicare Advantage beneficiariesRenal benefitsGLP-1RAsHeart failureBlack patientsDiabetes outcomesSpecialty careVascular diseaseBiopsychosocial factorsPatientsDiabetesSGLT2iIn-home Visits and Subsequent Health Outcomes in Medicare Advantage Beneficiaries With Coronary Artery Disease, Diabetes, Hypertension, and Depression
Smolderen K, Heath K, Ameli O, Spencer D, Natwick T, Musich S, Miedico T, Mena-Hurtado C. In-home Visits and Subsequent Health Outcomes in Medicare Advantage Beneficiaries With Coronary Artery Disease, Diabetes, Hypertension, and Depression. Medical Care 2023, 61: 366-376. PMID: 37167558, DOI: 10.1097/mlr.0000000000001850.Peer-Reviewed Original ResearchConceptsPrimary care visitsCoronary artery diseaseMajor adverse cardiovascular eventsFirst primary care visitAdverse cardiovascular eventsCare visitsWait-list control groupHome visitsArtery diseaseList control groupControl groupCardiovascular eventsCare metricsOptum Labs Data WarehouseHigh-morbidity conditionsMedicare Advantage populationInpatient care episodesMedicare Advantage beneficiariesRetrospective data analysisSubsequent health outcomesIndex dateSecondary outcomesEmergency visitsPrimary outcomeInpatient stay
2022
Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events
Smolderen K, Ameli O, Chaisson C, Heath K, Mena-Hurtado C. Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events. AJPM Focus 2022, 1: 100016. PMID: 37791014, PMCID: PMC10546509, DOI: 10.1016/j.focus.2022.100016.Peer-Reviewed Original ResearchMajor adverse limb eventsPeripheral artery diseaseAdverse limb eventsMajor cardiovascular eventsPeripheral artery disease (PAD) screeningArtery diseaseCardiovascular eventsLimb eventsCause mortalityOne-yearDisease screeningPeripheral vascular interventionsCardiovascular risk managementCause mortality ratesHome health visitsMedicare Advantage beneficiariesCardiovascular medicationsHealth visitsRevascularization proceduresHealthcare utilizationLandmark analysisSimilar riskVascular interventionsClaims dataMortality rateThe Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk
Smolderen KG, Heath K, Scherr T, Bauzon SR, Howell AN, Mena-Hurtado C. The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk. Journal Of Vascular Surgery 2022, 75: 2054-2064.e3. PMID: 35181520, DOI: 10.1016/j.jvs.2022.01.134.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPeripheral artery diseaseUnadjusted hazard ratioLower extremity peripheral artery diseaseHazard ratioMedicare Advantage beneficiariesCause mortalityElectronic medical recordsArtery diseaseMajor adverse cardiovascular event riskAdverse cardiovascular eventsAtherosclerotic risk factorsMedicare Advantage populationCardiovascular event riskAnnual health assessmentPrimary care providersPatients' electronic medical recordsRisk of mortalityScreening resultsPositive screening resultsMACE ratePAD screeningCardiovascular eventsMultivariable adjustmentScreening status
2021
Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020
Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020. Leukemia & Lymphoma 2021, 63: 1180-1190. PMID: 34913805, DOI: 10.1080/10428194.2021.2012666.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOverall survivalMedicare Advantage beneficiariesMyeloid leukemiaEconomic burdenFirst-line treatment choiceMedian overall survivalMedicare Advantage patientsUnmet medical needSupportive careAgent monotherapyAML patientsClinical outcomesContemporary cohortTreatment patternsAdvantage patientsTreatment choicePatient managementMedical needHealthcare expendituresPatientsOlder adultsLeukemiaPresent studySurvivalReal-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open 2021, 4: e2130587. PMID: 34677594, PMCID: PMC8536955, DOI: 10.1001/jamanetworkopen.2021.30587.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsSecondary end pointsMyocardial infarctionClinical trialsCardiovascular diseaseProstate cancerCardiovascular eventsEnd pointRisk of MACELarge US administrative claims databasePropensity-matched cohort studyUS administrative claims databasePropensity score-matched patientsAdverse cardiovascular eventsPrimary end pointAdministrative claims databaseProportional hazards regressionRandomized clinical trialsAdministrative claims dataTrial eligibility criteriaMedicare Advantage beneficiariesProstate cancer treatmentReal-world evidenceElectronic health recordsCardiovascular outcomesSecond-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.
McCoy RG, Van Houten HK, Karaca-Mandic P, Ross JS, Montori VM, Shah ND. Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities. Diabetes Care 2021, 44: 2302-2311. PMID: 34348996, PMCID: PMC8929191, DOI: 10.2337/dc20-2977.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsGLP-1RAsHeart failureRelative risk ratiosDPP-4iMyocardial infarctionOlder patientsCerebrovascular diseaseCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsType 2 diabetes managementDPP-4i therapySecond-line therapyCotransporter 2 inhibitorsPrior myocardial infarctionPeptidase-4 inhibitorsOptumLabs Data WarehouseType 2 diabetesMedicare Advantage beneficiariesMedication classesSGLT2i therapyClinical factorsRisk ratioComparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open 2021, 4: e2035792. PMID: 33523188, PMCID: PMC7851726, DOI: 10.1001/jamanetworkopen.2020.35792.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsCommercial insurance beneficiariesMedicare Advantage beneficiariesDPP-4i treatmentGLP-1RAsType 2 diabetesInsurance beneficiariesMedicare AdvantageGlucose levelsGlucagonlike Peptide-1 Receptor AgonistsPeptide-1 receptor agonistsHealth plansCommercial health insurance plansGLP-1RA treatmentRetrospective cohort studyCotransporter 2 inhibitorsInitiation of treatmentPeptidase-4 inhibitorsLow-income patientsSeparate logistic regression modelsAdministrative claims dataCommercial health plansAdjusted annual rateLogistic regression models
2020
Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions
Feder SL, Canavan ME, Wang S, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal Of Palliative Medicine 2020, 24: 195-204. PMID: 32673139, PMCID: PMC7840305, DOI: 10.1089/jpm.2020.0193.Peer-Reviewed Original ResearchConceptsCardiopulmonary conditionsOpioid useMedicare Part D prescription claimsPatterns of opioidSevere pain interferenceUse of opioidsInitiation of opioidsMedicare Advantage beneficiariesNon-Hispanic blacksSelf-reported historyNon-Hispanic whitesOpioid prescribingSevere painNoncancer conditionsPain assessmentPain interferencePrescription claimsAdjusted proportionObservational studyPainPatientsOpioidsLogistic regressionOne-yearCancer
2019
Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes
Rodriguez-Gutierrez R, Herrin J, Lipska KJ, Montori VM, Shah ND, McCoy RG. Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes. JAMA Network Open 2019, 2: e1913249. PMID: 31603490, PMCID: PMC6804020, DOI: 10.1001/jamanetworkopen.2019.13249.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAsianBlack or African AmericanComorbidityDiabetes ComplicationsEthnicityFemaleHispanic or LatinoHospital Bed Capacity, 300 to 499Hospital Bed Capacity, 500 and overHospitals, UniversityHospitals, VoluntaryHumansIncomeMaleMiddle AgedMinority GroupsPatient ReadmissionRacial GroupsRetrospective StudiesUnited StatesWhite PeopleConceptsCause readmissionIndex hospitalizationBlack patientsWhite patientsUS adultsHigh riskAdministrative claims data setsHospital-level risk factorsEthnic differencesLarge hospitalsPlace of hospitalizationDays of dischargeRetrospective cohort studyLow-income patientsMedicare Advantage beneficiariesSystem-level factorsClaims data setsHealth care qualityRace/ethnicityCohort studyReadmission ratesAdult patientsHospital readmissionHispanic patientsReadmission riskDifferences in Hospitalizations Between Fee-for-Service and Medicare Advantage Beneficiaries
Ndumele CD, Elliott MN, Haviland AM, Burkhart Q, Orr N, Gaillot S, Cleary PD. Differences in Hospitalizations Between Fee-for-Service and Medicare Advantage Beneficiaries. Medical Care 2019, 57: 8-12. PMID: 30339575, DOI: 10.1097/mlr.0000000000001000.Peer-Reviewed Original ResearchConceptsFFS coverageHospitalization ratesMedicare AdvantageMultivariable logistic regression modelMA enrolleesRate of hospitalizationLower hospitalization ratesPatterns of careMedicare Advantage beneficiariesLogistic regression modelsMedicare Consumer AssessmentHospital admissionRetrospective studyHealth characteristicsService useHospitalizationHealth statusHealthcare providersEnrollee demographicsConsumer AssessmentEnrolleesSystem surveySignificant age differencesMA enrollmentMA respondents
2018
Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
Jeffery MM, Hooten WM, Henk HJ, Bellolio MF, Hess EP, Meara E, Ross JS, Shah ND. Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study. The BMJ 2018, 362: k2833. PMID: 30068513, PMCID: PMC6066997, DOI: 10.1136/bmj.k2833.Peer-Reviewed Original ResearchConceptsMedicare Advantage beneficiariesAverage daily doseDisabled Medicare beneficiariesAged Medicare beneficiariesRetrospective cohort studyDaily doseOpioid useMedicare beneficiariesLong-term useCohort studyCommercial beneficiariesStudy periodUse prevalenceOpioid use prevalenceHigh rateMedicare Advantage populationTerm useAge 65 yearsOpioid use ratesAdministrative claims dataAverage daily dosesProportion of beneficiariesQuarterly prevalenceMorphine equivalentsOpioid prescriptionsHigh-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions
MCCOY R, HOUTEN H, LIPSKA K, SHAH N. High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1652-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseChronic obstructive pulmonary diseaseMajority of patientsHeart failureMyocardial infarctionSerious comorbiditiesGlycemic controlCerebrovascular diseaseChronic conditionsHigh-risk medication usePlurality of patientsProportion of patientsObstructive pulmonary diseaseStage renal diseaseUse of insulinOptumLabs Data WarehouseTight glycemic controlHigh-risk drugsSerious chronic conditionsMedicare Advantage beneficiariesGlycemic targetsUrinary incontinenceMedication usePeripheral neuropathyAdherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.
Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2018, 16: 526-534. PMID: 29752327, DOI: 10.6004/jnccn.2018.7001.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsBreast cancerDecreased likelihoodDefinitive breast cancer surgeryLikelihood of mammographySurvivorship care guidelinesCurative-intent treatmentProportion of patientsNonmetastatic breast cancerResidual breast tissueBreast cancer surgeryAdministrative claims dataBreast imagingBreast cancer treatmentMedicare Advantage beneficiariesBreast surveillanceInsured cohortPatient characteristicsAnnual mammographyCancer surgeryCare guidelinesBreast surgeryHealthcare useBlack race
2017
Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use
Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, Borgundvaag B, Shah ND, Bellolio MF. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Annals Of Emergency Medicine 2017, 71: 326-336.e19. PMID: 28967517, PMCID: PMC6295192, DOI: 10.1016/j.annemergmed.2017.08.042.Peer-Reviewed Original ResearchConceptsLong-term opioid useNon-ED settingsOpioid-naive patientsLong-term useOpioid prescriptionsOpioid useCharacteristics of prescriptionsPrescription opioid useLow daily dosesAdministrative claims dataRate of progressionDisabled Medicare beneficiariesMedicare Advantage beneficiariesED prescriptionGuideline concordancePatients 56Patients 58Opioid prescribingCDC guidelinesPrevention guidelinesDaily dosesEmergency departmentCDC recommendationsDays' supplyInclusion criteriaTrends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.Peer-Reviewed Original ResearchConceptsOmalizumab initiationAsthma controlICS-LABAPatient selectionLow adherenceBetter asthma controlCohort of nonusersSuboptimal patient selectionPoor asthma controlLow adherence ratesPatient-level characteristicsLarge US databaseMedicare Advantage beneficiariesAsthma biologicsExacerbation frequencyOmalizumab useIncident useComparison cohortICS/Medication adherenceAdherence ratesPrevalent usersAdministrative claimsAsthmaUtilization trendsHospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events
McCoy RG, Lipska KJ, Herrin J, Jeffery MM, Krumholz HM, Shah ND. Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events. Journal Of General Internal Medicine 2017, 32: 1097-1105. PMID: 28685482, PMCID: PMC5602759, DOI: 10.1007/s11606-017-4095-x.Peer-Reviewed Original ResearchConceptsDiabetes Complications Severity IndexSevere dysglycemiaIndex hospitalizationMedicare Advantage beneficiariesRisk factorsBetter care transitionsComplications Severity IndexPost-discharge managementIndependent risk factorYounger patient ageOptumLabs Data WarehouseStrong risk factorYears of ageBackgroundHospital readmissionsDesignRetrospective analysisCause readmissionUnplanned readmissionPatient agePrior hospitalizationReadmission ratesYounger patientsHeart failureHospital readmissionSevere hypoglycemiaDiabetes complications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply